NCCN Guidelines™ Version 2.2017 膀胱癌 目次 膀胱癌

1 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn ) nccn nccn guidelines Version nccn Clinical Practice guidelines in Oncology ( nccn guidelines ) nccn 2019 4 2019 7 10 BCG MS-11 AUA BCG Shortage Notice 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn ) nccn nccn guidelines Version nccn *Thomas W. Flaig, MD /Chair University of Colorado Cancer Center *Philippe E. Spiess, MD, MS /Vice Chair Moffitt Cancer Center Neeraj Agarwal, MD Huntsman Cancer Institute at the University of Utah Rick Bangs, MBA Patient Advocate Stephen A.

2 Boorjian, MD Mayo Clinic Cancer Center Mark K. Buyyounouski, MD, MS Stanford Cancer Institute *Sam Chang, MD, MBA Vanderbilt-Ingram Cancer Center Tracy M. Downs, MD University of Wisconsin Carbone Cancer Center Jason A. Efstathiou, MD, DPhil Massachusetts General Hospital Cancer Center Terence Friedlander, MD UCSF Helen Diller Family Comprehensive Cancer Center *Richard E. Greenberg, MD Fox Chase Cancer Center Khurshid A. Guru, MD Roswell Park Comprehensive Cancer Center Harry W. Herr, MD Memorial Sloan Kettering Cancer Center nccn guidelines Panel Disclosures Christopher Hoimes, MD Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute *Brant A. Inman, MD, MSc Duke Cancer Institute Masahito Jimbo, MD, PhD, MPH University of Michigan Rogel Cancer Center A.

3 Karim Kader, MD, PhD UC San Diego Moores Cancer Center Subodh M. Lele, MD Fred & Pamela Buffett Cancer Center Joshua J. Meeks, MD, PhD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Jeff Michalski, MD, MBA Siteman Cancer Center at Barnes- Jewish Hospital and Washington University School of Medicine Jeffrey S. Montgomery, MD, MHSA University of Michigan Rogel Cancer Center Lakshminarayanan Nandagopal, MD University of Alabama at Birmingham Comprehensive Cancer Center Lance C. Pagliaro, MD Mayo Clinic Cancer Center Sumanta K. Pal, MD City of Hope National Medical Center Anthony Patterson, MD St. Jude Children s Research Hospital/ The University of Tennessee Health Science Center Elizabeth R. Plimack, MD, MS Fox Chase Cancer Center Kamal S.

4 Pohar, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Michael Porter, MD, MS Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Mark A. Preston, MD, MPH Dana-Farber/Brigham and Women s Cancer Center Wade J. Sexton, MD Moffitt Cancer Center Arlene O. Siefker-Radtke, MD The University of Texas MD Anderson Cancer Center Jonathan Tward, MD, PhD Huntsman Cancer Institute at the University of Utah Jonathan Wright, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance nccn Lisa Gurski, PhD Alyse Johnson-Chilla, MS / / / / * 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn )

5 nccn nccn guidelines Version nccn BL-1 Tis / BL-1 2 BL-2 cTa cT1 Tis BL-3 / BL-1 II cT2, N0 BL-4 IIIA cT3, N0 cT4a, N0 cT1-cT4a, N1 BL-6 IIIB cT1-cT4a, N2,3 BL-7 IVA cT4b, Any N, M0 Any T, Any N, M1a BL-8 BL-9 BL-10 / BL-A) BL-B BL-C BL-D BL-E BL-F BL-G BL-H UTT-1 UTT-2 UCP-1 PCU-1 ST-1 nccn nccn National Comprehensive Cancer Network nccn nccn National Comprehensive Cancer Network nccn nccn 2019 nccn nccn nccn 2A

6 nccn nccn nccn 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn ) nccn nccn guidelines Version UPDATES nccn 2019 3 2019 4 MS-1 nccn 2019 2 2019 3 BL-7 / w FGFR3 FGFR2 FGFR RGQ RT-PCR BL-8 BL-9 bb FGFR3 FGFR2 FGFR RGQ RT-PCR BL-G 3 of 5 FGFR3 FGFR2 erdafitinib BL-1 / c 35 BL-F BL-3 BL-2 j

7 BL-3 2 nccn 2019 1 2019 2 BCG AUA BL-F 1 of 3 BCG 3 BCG 2 MS-11 BCG nccn 2018 4 2019 1 INTRO 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn ) nccn nccn guidelines Version nccn 2018 4 2019 1 BL-3 Tis cTa cT1 high grade n cTa cT1 cTa 2B cT1 2A.

8 N BL-G 4 of 5 BL-4 BL-5 2A 1 BL-6 u BL-6 BL-6 v N1 BL-7 / BL-8 2 3 x BL-9 .. / BL-A 2 of 5 2 2 X X CT .. 3 2 X X CT 4 2 " X X CT BL-A 4 of 5 / 2 X CT X T1 CT BL-B 1 of 4 TURBT TURBT/ TURBT.

9 UPDATES 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn ) nccn nccn guidelines Version BL-B 2 of 4 cT2 T1 / high grade, cT1 4 cT2 cT4a .. 2 BL-E BL-F 1 of 3 BL-G 3 of 5 BL-H 9 RT 5-FU C.

10 Coen JJ, Zhang P, Saylor PJ, et al. Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712 A randomized phase 2 multicenter trial [Abstract]. J Clin Oncol 2018;36:6_suppl, 408. UTT-1 UTT-2 / b UTT-2 UCP-1 X / CT PCU-2 RT d .. PCU-3 cN1/cN2 UPDATES 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn ) nccn nccn guidelines Version INTRO nccn nccn 2019 4 07/10/19 2019 National Comprehensive Cancer Network ( nccn )